Japan’s Takeda optimizes global production network

Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) has decided to focus its Osaka plant (Osaka Prefecture, Japan) to become a specialty manufacturing site for prostate and breast cancer and endometriosis treatment Leuplin/Lupron (leuprorelin), one of firm’s main products.

It will transfer the manufacturing of solid products to its plants at Hikari (Yamaguchi Prefecture, Japan) and Oranienburg (Brandenburg, Germany), a process that will be completed during fiscal year 2018, in order to optimize its global manufacturing network.

The Osaka plant will continue to contribute to the company’s business as a specialty manufacturing site for Leuplin. Meanwhile, the Hikari Plant will further expand its capacity to produce various ethical medicines, including anticancer drugs and vaccines. The Oranienburg Plant which has excellent productivity will further enhance its capacity and continue to deliver products to many countries.